Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AMINOSYN II 5% is an injectable amino acid formulation used for parenteral nutrition in patients requiring intravenous nutritional support. It provides essential and non-essential amino acids to maintain protein metabolism and nutritional status in hospitalized or critically ill patients unable to receive oral or enteral nutrition. The product works by delivering amino acids directly into the bloodstream for systemic protein synthesis and metabolic support.
This legacy injectable nutrition product faces LOE approaching, signaling a contracting commercial footprint with likely reduced team size and marketing investment focus shifting to cost management and retention strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
The Effects of a Dialysis-Specific Formula Rich in Branched-Chain Amino Acids, Omega-3, and Dietary Fiber on Nutritional Status
Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
The Glucagonotropic Effect of Amino Acids in Humans
Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU)
Bioavailability of Plant Protein Amino Acids
Worked on AMINOSYN II 5% at ICU Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on AMINOSYN II offers limited career growth potential given the product's mature, LOE-approaching lifecycle stage. Opportunities are concentrated in commercial operations, sales, and supply chain roles focused on customer retention and margin management rather than expansion or launch activities.